N D James
Overview
Explore the profile of N D James including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
2369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parker C, Petersen P, Cook A, Clarke N, Catton C, Cross W, et al.
Ann Oncol
. 2024 Apr;
35(7):656-666.
PMID: 38583574
Background: The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT versus an observation policy with salvage...
2.
Gilbert D, Nankivell M, Rush H, Clarke N, Mangar S, Al-Hasso A, et al.
Clin Oncol (R Coll Radiol)
. 2023 Nov;
36(1):e11-e19.
PMID: 37973477
Aims: Androgen deprivation therapy (ADT), usually achieved with luteinising hormone releasing hormone analogues (LHRHa), is central to prostate cancer management. LHRHa reduce both testosterone and oestrogen and are associated with...
3.
Sutera P, Shetty A, Hakansson A, Van der Eecken K, Song Y, Liu Y, et al.
Ann Oncol
. 2023 May;
34(7):605-614.
PMID: 37164128
Background: Metastatic castration-sensitive prostate cancer (mCSPC) is commonly classified into high- and low-volume subgroups which have demonstrated differential biology, prognosis, and response to therapy. Timing of metastasis has similarly demonstrated...
4.
Baxter L, Gordon N, Ott S, Wang J, Patel P, Goel A, et al.
Sci Rep
. 2023 Jan;
13(1):1060.
PMID: 36658180
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1 frequently occur in bladder cancer (BC). These mutations could function as biomarkers for the non-invasive detection...
5.
Clarke N, Ali A, Ingleby F, Hoyle A, Amos C, Attard G, et al.
Ann Oncol
. 2020 Feb;
31(3):442.
PMID: 32067690
No abstract available.
6.
Clarke N, Ali A, Ingleby F, Hoyle A, Amos C, Attard G, et al.
Ann Oncol
. 2019 Sep;
30(12):1992-2003.
PMID: 31560068
Background: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on...
7.
Vale C, Fisher D, White I, Carpenter J, Burdett S, Clarke N, et al.
Ann Oncol
. 2018 May;
29(5):1249-1257.
PMID: 29788164
Background: Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or...
8.
Sydes M, Spears M, Mason M, Clarke N, Dearnaley D, de Bono J, et al.
Ann Oncol
. 2018 Mar;
29(5):1235-1248.
PMID: 29529169
Background: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation of drug...
9.
Spears M, James N, Sydes M
Ann Oncol
. 2017 Sep;
28(10):2327-2330.
PMID: 28961849
No abstract available.
10.
James N, Sydes M, Clarke N, Ritchie A, Parmar M
Clin Oncol (R Coll Radiol)
. 2016 Aug;
28(10):666-7.
PMID: 27477123
No abstract available.